April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA82
Academic Journal
Clinical trials suggest treating genotype 1 hepatitis C with combination treatment for 12 months and genotype 2/3 for 6 months. However, this prolonged course of treatment reduces compliance and puts enormous strain on budgets, thereby limiting its use. This study has shown that 3 months treatment may be adequate for patients with genotype 2/3 hepatitis C; however the higher role of relapse in genotype 1 may indicate the need for 6-12 months combination therapy.


Related Articles

  • Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects. Bartels, Doug J.; Yi Zhou; Zhang, Eileen Z.; Marcial, Michelle; Byrn, Randal A.; Pfeiffer, Thomas; Tigges, Ann M.; Adiwijaya, Bambang S.; Chao Lin; Kwong, Ann D.; Kieffer, Tara L. // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p800 

    Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response. Methods....

  • Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. El Awady, Mostafa K.; El Din, Noha G. Badr; El Garf, Wael T.; Youssef, Samar S.; Omran, Moataza H.; El Abd, Jasmin; Goueli, Said A. // Cancer Cell International;2006, Vol. 6, p18 

    Background: Hepatitis C (HCV) viral infection is a serious medical problem in Egypt and it has a devastating impact on the Egyptian economy. It is estimated that over 15% of Egyptians are infected by the virus and thus finding a cure for this disease is of utmost importance. Current therapies...

  • CLINIC ROUNDUP.  // BioWorld Today;10/30/2008, Vol. 19 Issue 212, p6 

    This section offers news related to clinical trials. Dosing of ANA598 in patients chronically infected with hepatitis C virus has been started by Anadys Pharmaceuticals Inc. in a Phase Ib study. Enrollment has been completed in Chelsea Therapeutics International Limited's Phase II trial...

  • Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Spada, E.; Mele, A.; Berton, A.; Ruggeri, L.; Ferrigno, L.; Garbuglia, A. R.; Perrone, M. P.; Girelli, G.; Del Porto, P.; Piccolella, E.; Mondelli, M. U.; Amoroso, P.; Cortese, R.; Nicosia, A.; Vitelli, A.; Folgori, A. // Gut;Nov2004, Vol. 53 Issue 11, p1673 

    Background/Aims: Hepatitis C virus (HCV) infection results in a high frequency of chronic disease. The aim of this study was to identify early prognostic markers of disease resolution by performing a comprehensive analysis of viral and host factors during the natural course of acute HCV...

  • Reemergence of Hepatitis C Virus after 8.5 Years in a Patient with Hypogammaglobulinemia: Evidence for an Occult Viral Reservoir. Lee, William M.; Polson, Julie E.; Carney, D. Spencer; Sahin, Bogachan; Gale, Jr., Michael // Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p1088 

    The question of whether viruses persist after apparent clearance of infection remains unanswered. Here, we describe a patient with hypogammaglobulinemia whose acute hepatitis C virus (HCV) infection appeared to resolve after receipt of interferon therapy, relapse immediately, and then clear...

  • ANA773.  // Biotech Financial Reports;Sep2009, Vol. 16 Issue 9, p8 

    The article offers information on the phase I clinical trial of ANA773, an oral inducer of endogenous interferons acting via the toll like receptor 7 pathway, by Anadys Pharmaceuticals Inc. in San Diego, California. It notes the company' report of evidence of viral load reduction in the majority...

  • Flow Diversion in Aneurysms Trial: the Design of the FIAT study. RAYMOND, J.; DARSAUT, T. E.; GUILBERT, F.; WEILL, A.; ROY, D. // Interventional Neuroradiology;jun2011, Vol. 17 Issue 2, p147 

    Intracranial aneurysms, particularly large and giant, fusiform or recurrent aneurysms are increasingly treated with flow diverters (FDs), a recently introduced and approved neurovascular device. While some rare cases may not be treated any other way, in most patients a more conventional,...

  • Amicus' Phase III with Amigal Short, Sweet; no Fabrazyme. Osborne, Randy // BioWorld Today;6/23/2009, Vol. 20 Issue 119, p1 

    The article reports on the Phase III trial using Amigal against Fabry disease to be conducted by Amicus Therapeutics Inc. It is noted that many expected that the company would not be able to push through with the third phase of the 60-patient, six-month trial. Under the trial, patients will be...

  • From the Editor. Peach, Richard K. // American Journal of Speech-Language Pathology;May2004, Vol. 13 Issue 2, p98 

    This article addresses some concerns on the utilization of randomized clinical trials (RCT) to determine the efficacy of clinical interventions in speech-language pathology. The author notes that in order to improve the overall credibility of the positive outcomes associated with many...


Read the Article


Sign out of this library

Other Topics